> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Reg Review Period for Glaxo’s Shingrix Vaccine
- URL: https://www.fdaweb.com/reg-review-period-for-glaxos-shingrix-vaccine/
- Published: 2019-09-09T12:00:00.000Z
- Updated: 2026-09-15T01:48:27.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144950

*Federal Register* notice: FDA has determined the regulatory review period for patent extension purposes for GlaxoSmithKline Biologicals’ Shingrix (zoster vaccine recombinant, adjuvanted), a vaccine indicated for preventing herpes zoster (shingles) in adults aged 50 years and older. The review period is 3,257 days, which includes 2,892 days that occurred during the testing phase and 365 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-09-06/pdf/2019-19205.pdf?ref=fdaweb.com).